表紙
市場調査レポート

Auris Medical Holding AG :製品パイプライン分析

Auris Medical Holding AG - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 321940
出版日 ページ情報 英文 31 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
Auris Medical Holding AG :製品パイプライン分析 Auris Medical Holding AG - Product Pipeline Review - 2015
出版日: 2015年09月30日 ページ情報: 英文 31 Pages
概要

Auris Medical AG は主に耳鳴りおよび難聴治療薬を開発している製薬会社です。同社はまた加齢に伴う内耳障害や、過度の騒音に曝されたり、耳毒性薬物暴露のために発症した音響刺激過度治療の薬も提供しています。

当レポートでは、Auris Medical Holding AGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Auris Medical Holding AGの基本情報

Auris Medical Holding AGの概要

  • 主要情報
  • 企業情報

Auris Medical Holding AG:R&Dの概要

  • 主な治療範囲

Auris Medical Holding AG- Pipeline Review

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Auris Medical Holding AG:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Auris Medical Holding AG:薬剤プロファイル

  • esketamine hydrochloride
  • XG-102
  • AM-102
  • AM-123

Auris Medical Holding AG:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Auris Medical Holding AG:最近のパイプライン動向

Auris Medical Holding AG:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07646CDB

Summary

Global Markets Direct's, 'Auris Medical Holding AG - Product Pipeline Review - 2015', provides an overview of the Auris Medical Holding AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Auris Medical Holding AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Auris Medical Holding AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Auris Medical Holding AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Auris Medical Holding AG's pipeline products

Reasons to buy

  • Evaluate Auris Medical Holding AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Auris Medical Holding AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Auris Medical Holding AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Auris Medical Holding AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Auris Medical Holding AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Auris Medical Holding AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Auris Medical Holding AG Snapshot
    • Auris Medical Holding AG Overview
    • Key Information
    • Key Facts
  • Auris Medical Holding AG - Research and Development Overview
    • Key Therapeutic Areas
  • Auris Medical Holding AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Auris Medical Holding AG - Pipeline Products Glance
    • Auris Medical Holding AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Auris Medical Holding AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Auris Medical Holding AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Auris Medical Holding AG - Drug Profiles
    • esketamine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • XG-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-102
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AM-123
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Auris Medical Holding AG - Pipeline Analysis
    • Auris Medical Holding AG - Pipeline Products by Target
    • Auris Medical Holding AG - Pipeline Products by Route of Administration
    • Auris Medical Holding AG - Pipeline Products by Molecule Type
    • Auris Medical Holding AG - Pipeline Products by Mechanism of Action
  • Auris Medical Holding AG - Recent Pipeline Updates
  • Auris Medical Holding AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Auris Medical Holding AG, Key Information
  • Auris Medical Holding AG, Key Facts
  • Auris Medical Holding AG - Pipeline by Indication, 2015
  • Auris Medical Holding AG - Pipeline by Stage of Development, 2015
  • Auris Medical Holding AG - Monotherapy Products in Pipeline, 2015
  • Auris Medical Holding AG - Partnered Products in Pipeline, 2015
  • Auris Medical Holding AG - Partnered Products/ Combination Treatment Modalities, 2015
  • Auris Medical Holding AG - Phase III, 2015
  • Auris Medical Holding AG - Phase II, 2015
  • Auris Medical Holding AG - Preclinical, 2015
  • Auris Medical Holding AG - Pipeline by Target, 2015
  • Auris Medical Holding AG - Pipeline by Route of Administration, 2015
  • Auris Medical Holding AG - Pipeline by Molecule Type, 2015
  • Auris Medical Holding AG - Pipeline Products by Mechanism of Action, 2015
  • Auris Medical Holding AG - Recent Pipeline Updates, 2015
  • Auris Medical Holding AG, Subsidiaries

List of Figures

  • Auris Medical Holding AG - Pipeline by Top 10 Indication, 2015
  • Auris Medical Holding AG - Pipeline by Stage of Development, 2015
  • Auris Medical Holding AG - Monotherapy Products in Pipeline, 2015
  • Auris Medical Holding AG - Partnered Products in Pipeline, 2015
  • Auris Medical Holding AG - Pipeline by Top 10 Route of Administration, 2015
  • Auris Medical Holding AG - Pipeline by Top 10 Molecule Type, 2015
  • Auris Medical Holding AG - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top